Synaptogenix Inc (SNPX)

[runncoach]

That could benefit us at some point but is intended to guide companies testing drugs for earlier stages of Alzheimer's. They never address severe.

Basically trying to treat alzheimer's at earlier stages is hard to quantitatively measure because while memory issues are prevalent, patients may still be able to perform daily tasks such as getting dressed. Those types of measurements are hard to distinguish from a placebo group, leaving only a cognitive score to meet the endpoint. I think moving forward they will use a cognitive score coupled with scientific bio markers or other scientific evidence that the drug is working better than placebo instead of just daily activities testing.